Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENPRESSE-28 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ENPRESSE-28 is a combined hormonal contraceptive containing ethinyl estradiol and desogestrel. It acts by suppressing gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering the endometrium.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy in women who elect to use oral contraceptives
Prevention of pregnancy (FDA-approved)
1 tablet (ethinyl estradiol 0.035 mg / norgestimate 0.25 mg) orally once daily for 21 days, followed by 7 placebo days.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life is 18-24 hours, allowing once-daily dosing; steady-state achieved within 5-7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol is primarily metabolized by CYP3A4; desogestrel is a prodrug converted to its active metabolite etonogestrel, which is further metabolized by CYP3A4, CYP2C9, and CYP2C19. Both undergo extensive first-pass metabolism.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Primarily renal excretion as unchanged drug (70-80%) and glucuronide conjugate (15-20%); biliary/fecal elimination accounts for <5%.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
98% bound primarily to albumin and alpha-1 acid glycoprotein.
~99% bound to serum albumin and sex hormone-binding globulin.
0.2 L/kg; indicates distribution primarily in extracellular fluid with minimal tissue binding.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 40-50%; reduced by high-fat meal (10-20% decrease).
Oral: ~70% due to first-pass metabolism.
No dosage adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; contraindicated in patients with renal disease.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute hepatic disease or history of cholestatic jaundice with prior oral contraceptive use. No adjustment provided for mild impairment; avoid use in Child-Pugh B or C.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Safety and efficacy not established in females before menarche. Post-menarche: use same dosing as adults (1 tablet daily for 21 days, then 7 placebo days).
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use after menopause. No specific geriatric dosing considerations.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with the number of cigarettes smoked, and is quite marked in women over 35 years of age. Women over 35 who smoke should not use combination oral contraceptives.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thromboembolic disorders: Venous and arterial thrombotic events, including pulmonary embolism, stroke, and myocardial infarction, especially in smokers and women with risk factors.,Hepatic disease: Discontinue if jaundice or hepatotoxicity develops.,Hypertension: Monitor blood pressure; discontinue if hypertension occurs.,Carcinoma of the breast and reproductive organs: Use with caution in women with a history of breast cancer or hormone-sensitive tumors.,Gallbladder disease: Increased risk of gallbladder disease.,Carbohydrate and lipid metabolism: May impair glucose tolerance and affect lipid levels.,Headache: Evaluate new or worsening migraine patterns.,Hereditary angioedema: Can trigger or exacerbate symptoms.,Depression: Monitor for development or worsening of depression.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Hypersensitivity to any component,Current or history of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease (current or history),Thrombogenic valvular or rhythm disorders (e.g., atrial fibrillation),Uncontrolled hypertension (BP >160/100 mm Hg),Major surgery with prolonged immobilization,Diabetes mellitus with vascular involvement,Headaches with focal neurological symptoms or migraine with aura (age ≥35),Current or history of breast cancer or other estrogen-sensitive neoplasia,Active liver disease or history of liver tumors (benign or malignant),Undiagnosed abnormal uterine bleeding,Pregnancy (known or suspected),Cocarcinogenicity with hepatitis C drugs containing ombitasvir/paritaprevir/ritonavir (increased ALT elevations)
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4 and can increase ethinylestradiol levels, potentially increasing the risk of estrogen-related adverse effects (e.g., thromboembolism, hypertension). No other specific food interactions are clinically significant.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
FDA Pregnancy Category X. First trimester: High risk of fetal malformations including craniofacial defects, cardiac anomalies, and neural tube defects. Second and third trimesters: Continued risk of teratogenicity; contraindicated in pregnancy.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Contraindicated during breastfeeding. Small amounts excreted into breast milk; M/P ratio approximately 0.62. Potential for serious adverse effects in nursing infants, including cardiovascular and renal effects.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Not applicable as drug is contraindicated during pregnancy. No dose adjustment recommendations due to lack of safe use.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
ENPRESSE-28 is a combined oral contraceptive containing ethinylestradiol 0.035 mg and norgestimate 0.18/0.215/0.25 mg in a triphasic regimen. For missed pills, follow the CDC/USMEC guidelines: if one active pill is missed, take it as soon as remembered and continue schedule; if two or more are missed, take the most recent missed pill, discard others, use backup contraception for 7 days, and consider emergency contraception if unprotected intercourse occurred. Monitor for thromboembolic events, especially in smokers over 35, and counsel on increased risk. Concomitant use of certain anticonvulsants (e.g., phenytoin, carbamazepine), rifampin, or St. John's Wort may reduce contraceptive efficacy; consider alternative contraception. Assess for contraindications including migraine with aura, hypertension (>160/100), or history of DVT/PE.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time each day, starting on the first day of your menstrual period or the Sunday after your period begins as directed.,If you miss a pill, refer to the package insert for instructions; use backup contraception (condoms) if needed and consider emergency contraception if unprotected sex occurred.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding; these often improve within a few months.,This medication does not protect against sexually transmitted infections (STIs); use condoms for STI prevention.,Seek medical attention immediately for symptoms of blood clots such as sudden leg pain/swelling, chest pain, shortness of breath, severe headache, or vision changes.,Avoid grapefruit and grapefruit juice while taking this medication as it may increase estrogen levels and side effects.,Inform your healthcare provider of all medications and supplements you take, including St. John's Wort, antibiotics, and anticonvulsants, as they may reduce effectiveness.,Smoking while using this pill increases the risk of serious cardiovascular side effects; do not smoke, especially if you are over 35 years old.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENPRESSE-28 vs AFIRMELLE, answered by our medical review team.
ENPRESSE-28 is a Oral Contraceptive that works by ENPRESSE-28 is a combined hormonal contraceptive containing ethinyl estradiol and desogestrel. It acts by suppressing gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering the endometrium.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENPRESSE-28 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENPRESSE-28 is: 1 tablet (ethinyl estradiol 0.035 mg / norgestimate 0.25 mg) orally once daily for 21 days, followed by 7 placebo days.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENPRESSE-28 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENPRESSE-28 is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of fetal malformations including craniofacial defects, cardiac anomalies, and neural tube defects. Second and third trimesters:. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.